| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2019 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 20,000 | $31.43 | $628,586.00 | New | |
| Mar 13, 2019 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 18,725 | $82.00 | $1,535,453.75 | -2.3% | |
| Mar 13, 2019 | ANIP Ani Pharmaceuticals Inc | Schrepfer Robert W | SVP - New Bus Dev &Spec Sales | Sell | 11,796 | $64.44 | $760,167.67 | -7.6% | |
| Mar 13, 2019 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 60,000 | $33.32 | $1,998,932.42 | -4.0% | |
| Mar 12, 2019 | NBIX Neurocrine Biosciences Inc | Neurocrine Biosciences Inc | 10% Owner | Buy | 4,179,728 | $11.96 | $49,999,996.20 | New | |
| Mar 12, 2019 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 738 | $15.67 | $11,568.08 | -34.7% | |
| Mar 12, 2019 | ESPR Esperion Therapeutics, Inc. | Newton Roger S | Director | Sell | 25,000 | $50.06 | $1,251,500.00 | -4.4% | |
| Mar 12, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Stewart Robert A | President And CEO | Buy | 17,000 | $11.92 | $202,640.00 | New | |
| Mar 12, 2019 | LLY Eli Lilly & Co | Fry Stephen F | SVP, Hr &Diversity | Sell | 14,847 | $123.16 | $1,828,556.52 | -11.9% | |
| Mar 12, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 647 | $15.67 | $10,141.66 | -7.0% | |
| Mar 12, 2019 | BCRX Biocryst Pharmaceuticals Inc | Aselage Steve80 | Director | Buy | 2,000 | $8.30 | $16,600.00 | New | |
| Mar 12, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 715 | $15.69 | $11,218.21 | -100% | |
| Mar 12, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Bisaro Paul | Executive Chairman | Buy | 17,000 | $11.97 | $203,490.00 | New | |
| Mar 12, 2019 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 19,000 | $2.99 | $56,889.80 | +10.5% | |
| Mar 12, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 2,444 | $15.82 | $38,664.08 | -45.1% | |
| Mar 12, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, Growth Markets Commercial | Sell | 325 | $15.69 | $5,099.19 | -3.7% | |
| Mar 12, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 953 | $15.67 | $14,938.18 | -100% | |
| Mar 11, 2019 | ELAN Elanco Animal Health Inc | Urbanek David Alan | See Remarks | Buy | 2,021 | $0.00 | - | +16.9% | |
| Mar 11, 2019 | ELAN Elanco Animal Health Inc | Kinard David S | See Remarks | Buy | 7,977 | $0.00 | - | +54.7% | |
| Mar 11, 2019 | ELAN Elanco Animal Health Inc | Cabral Ramiro Martin | See Remarks | Buy | 1,227 | $0.00 | - | +10.7% | |
| Mar 11, 2019 | ELAN Elanco Animal Health Inc | Simmons Jeffrey N52 | Presiident, CEO &Director | Buy | 37,301 | $0.00 | - | +40.4% | |
| Mar 11, 2019 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 2,430 | $56.93 | $138,339.90 | -7.0% | |
| Mar 11, 2019 | ELAN Elanco Animal Health Inc | Schacht Aaron L | See Remarks | Buy | 1,227 | $0.00 | - | +9.7% | |
| Mar 11, 2019 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 920 | $0.00 | - | New | |
| Mar 8, 2019 | SNY Sanofi | Sanofi | 10% Owner | Sell | 131,115 | $412.17 | $54,041,315.54 | -0.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.